Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday, July 11th.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Separately, B. Riley reiterated a “buy” rating and set a $4.00 target price on shares of Ekso Bionics Holdings in a research report on Monday, May 15th.
Shares of Ekso Bionics Holdings (NASDAQ:EKSO) opened at 1.47 on Tuesday. The company’s market capitalization is $37.91 million. Ekso Bionics Holdings has a 52 week low of $0.99 and a 52 week high of $6.38. The firm has a 50 day moving average price of $1.99 and a 200 day moving average price of $2.64.
Ekso Bionics Holdings (NASDAQ:EKSO) last released its earnings results on Tuesday, May 9th. The company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.03. The company had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.38 million. Ekso Bionics Holdings had a negative return on equity of 798.93% and a negative net margin of 372.20%. Equities analysts forecast that Ekso Bionics Holdings will post ($0.72) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Cut to Hold at Zacks Investment Research” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2017/08/12/ekso-bionics-holdings-inc-nasdaqekso-cut-to-hold-at-zacks-investment-research-updated-updated-updated.html.
Large investors have recently bought and sold shares of the stock. Independence Advisors LLC acquired a new stake in Ekso Bionics Holdings during the second quarter worth approximately $1,840,000. Carl Domino Inc boosted its stake in Ekso Bionics Holdings by 262.4% in the first quarter. Carl Domino Inc now owns 46,966 shares of the company’s stock worth $193,000 after buying an additional 34,008 shares in the last quarter. National Planning Corp boosted its stake in Ekso Bionics Holdings by 116.2% in the second quarter. National Planning Corp now owns 234,450 shares of the company’s stock worth $537,000 after buying an additional 126,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Ekso Bionics Holdings by 32.9% in the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after buying an additional 176,197 shares in the last quarter. 4.55% of the stock is currently owned by institutional investors and hedge funds.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Ekso Bionics Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ekso Bionics Holdings Inc. and related companies.